FDAnews
www.fdanews.com/articles/75495-serono-to-develop-genmab-cancer-antibody-humax-cd4-deal-worth-up-to-215-mln-usd

SERONO TO DEVELOP GENMAB CANCER ANTIBODY HUMAX-CD4; DEAL WORTH UP TO 215 MLN USD

August 18, 2005

Genmab AS said it granted Serono SA worldwide rights to develop and market its HuMax-CD4 antibody for treatment of T-cell lymphomas, in a deal worth an initial 70 mln usd. The antibody, which has been granted fast track status by the US Food and Drug Administration, is currently being evaluated in a Phase III clinical trial. Under the terms of the agreement, Genmab will receive a license fee of 20 mln usd and Serono will also invest 50 mln usd in Genmab common stock, at a premium to the market price.

Forbes (http://www.forbes.com/business/feeds/afx/2005/08/18/afx2184347.html)